natgillin/translations-raw huggingface dataset:
The PFS results were consistent across all baseline and demographic subgroups evaluated, including prior therapy with tyrosine kinase inhibitors (which may have consisted of agents targeting pathways associated with anti-angiogenesis), RET mutational status (including subjects documented not to have RET mutations), prior anticancer or radiotherapy status, or the existence of bone metastases.
PFS rezultati su se pokazali konzistentnim u svim početnim i demografskim podskupinama koje su ispitivane, uključujući ispitanike s prethodnom terapijom inhibitorima tirozinskih kinaza (koje su se mogle sastojati od agensa koji ciljaju puteve povezane s anti-angiogenezom), RET mutacijski status (uključujući ispitanike koji dokumentirano nemaju mutacije RET-a), raniji antikancerogeni ili radioterapijski status ili postojanje metastaza u kostima.
The pH of the reconstituted solution is 4.0-6.0.
pH otopine nakon rekonstitucije je 4,0-6,0.
The pH of the reconstituted solution is 6.5-7.5.
pH rekonstituirane otopine je 6,5-7,5.
The pH of the reconstituted solution is 7.5-8.5.
pH rekonstituirane otopine je 7,5-8,5.
The pH of the reconstituted solution is approximately 7.0. Before further dilution, visually inspect the reconstituted solution in each vial for particulate matter and discoloration.
Prije daljnjeg razrjeđivanja vizualno pregledajte rekonstituiranu otopinu u svakoj bočici, sadrži li čestice i je li došlo do promjene boje.
The pharmacist educational material should contain:
Edukacijski materijali za ljekarnike trebaju sadržavati:
The pharmacist may compound a 6 mg/ml suspension from Ebilfumin 30 mg, 45 mg or 75 mg capsules using water containing 0.05 % w/v sodium benzoate added as a preservative.
Ljekarnik može pripremiti suspenziju koncentracije 6 mg/ml iz Ebilfumin kapsula od 30 mg, 45 mg ili 75 mg pomoću vode s 0,05 % m/v natrijeva benzoata koji se dodaje kao konzervans.
The pharmacist may compound a 6 mg/ml suspension from Tamiflu 30 mg, 45 mg or 75 mg capsules using water containing 0.05 % w/v sodium benzoate added as a preservative.
Ljekarnik može pripremiti suspenziju koncentracije 6 mg/ml iz Tamiflu kapsula od 30 mg, 45 mg ili 75 mg pomoću vode s 0,05 % m/V natrijeva benzoata koji je dodan kao konzervans.
The pharmacist must be familiar with the educational material of Instanyl nasal spray before using it in his/her organisation.
Ljekarnik mora poznavati edukacijski materijal o Instanyl spreju za nos prije nego ga koristi u svojoj ustanovi.
The pharmacist must be familiar with the educational material of PecFent nasal spray before using it in his/her organization
Ljekarnik mora biti upoznat s edukacijskim materijalom za PecFent sprej za nos prije nego što ga počne upotrebljavati u svojoj organizaciji.
The pharmacist must inform the patients that in order to prevent theft and misuse of Instanyl nasal spray they have to keep it in a safe place to avoid misuse and diversion.
Ljekarnik mora upozoriti bolesnike da radi prevencije krađe i zlouporabe Instanyl spreja za nos, moraju ga čuvati na sigurnom mjestu kako bi se izbjegla zlouporaba ili pogrešna primjena.
The pharmacist must inform the patients that in order to prevent theft and misuse of PecFent nasal spray they have to keep it in a safe place to avoid misuse and diversion
Ljekarnik mora upozoriti bolesnike da PecFent sprej za nos moraju držati na sigurnom mjestu kako bi izbjegli nepravilnu upotrebu i krađu.
The pharmacist must make use of the checklist for pharmacist
Ljekarnik mora koristiti kontrolnu listu za ljekarnike.
The pharmacist must make use of the checklist for pharmacist
Ljekarnik se mora koristiti podsjetnikom za provjeru za ljekarnike.
The pharmacist or nurse will calculate the exact dose you need.
Ljekarnik ili medicinska sestra izračunat će točnu dozu koju trebate.
The pharmacist should be aware that off label prescription and suspected abuse or misuse of Instanyl should be reported according to your local guidelines for adverse reactions reporting.
Ljekarnik mora biti svjestan da se propisivanje izvan indikacije i sumnja na pogrešnu primjenu Instanyla moraju prijaviti sukladno lokalnim smjernicama za prijavljivanje nuspojava.
The pharmacist will write the date of expiration on the bottle label in the black box next to "Use before".
Ljekarnik će napisati datum isteka roka valjanosti na naljepnicu boce, u predviđeni prostor pokraj navoda „Upotrijebiti do“.
The pharmacodynamic effect of factor VIIa gives rise to an increased local formation of factor Xa, thrombin and fibrin.
Farmakodinamički učinak faktora VIIa pojačava lokalno stvaranje faktora Xa, trombina i fibrina.
The pharmacodynamic effect of Ryzodeg is distinctively separated for the two components (Figure 1) and the resulting action profile reflects the individual components, the rapid-acting insulin aspart and the basal component insulin degludec.
Farmakodinamički učinak lijeka Ryzodeg jasno je odvojen za dva sastojka (slika 1), a dobiveni profil djelovanja odražava pojedinačne sastojke, brzodjelujući aspart inzulin i bazalni sastojak, degludek inzulin.
The pharmacodynamic effect of warfarin on International Normalized Ratio (INR) was not affected by macitentan.
Farmakodinamički učinak varfarina na međunarodni normalizirani omjer (INR) nije bio pod utjecajem macitentana.
The pharmacodynamic effects of Aerinaze tablets are directly related to that of its components.
Farmakodinamički učinci lijeka Aerinaze su izravno povezani s farmakodinamikom njegovih sastavnica.
The pharmacodynamic effects of Neparvis were evaluated after single and multiple dose administrations in healthy subjects and in patients with heart failure, and are consistent with simultaneous neprilysin inhibition and RAAS blockade.
Farmakodinamički učinci Neparvisa ocjenjivani su nakon primjene jednokratne i višekratnih doza u zdravih ispitanika i u bolesnika sa zatajenjem srca, te su u skladu s istodobnom inhibicijom neprilizina i blokadom RAAS-a.
The pharmacodynamic profile and the reported adverse reactions indicate that an effect is unlikely.
Farmakodinamički profil i prijavljene nuspojave upućuju na to da nije vjerojatno da ima učinka.
The pharmacodynamic properties of 64Cu-labelled medicinal products prepared by radiolabelling with Cuprymina, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakodinamička svojstva 64Cu-obilježenih lijekova pripremljenih radioobilježavanjem Cuprymina- om prije njegove primjene, ovisit će o prirodi lijeka koji će biti radioobilježen.
The pharmacodynamically predictable and most commonly reported adverse reactions are thirst, dry mouth and pollakiuria occurring in approximately 18%, 9% and 6% of patients.
Farmakodinamički predvidive i najčešće prijavljene nuspojave su žeđ, suha usta i polakizurija koji se pojavljuju u otprilike 18%, 9% odnosno 6% bolesnika.
The pharmacodynamically predictable and most commonly reported adverse reactions are thirst, polyuria, nocturia, and pollakiuria occurring in approximately 55%, 38%, 29% and 23% of patients, respectively.
Farmakodinamički predvidive i najčešće prijavljene nuspojave bile su žeđ, poliurija, nikturija i polakisurija u otprilike 55%, 38%, 29% odnosno 23% bolesnika.
The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 – 50 mg).
Ocijenjen je farmakokinetički/farmakodinamički (PK/PD) odnos između koncentracije apiksabana u plazmi i nekoliko farmakodinamičkih mjera ishoda (anti-FXa aktivnost, INR, PV, aPTV) nakon primjene širokog raspona doza (0,5 mg - 50 mg).
The pharmacokinetic absorption profile will repeat with each application to a new skin site, therefore with each new application, absorption will be lower initially.
Farmakokinetički profil apsorpcije ponovit će se sa svakom primjenom na drugo mjesto na koži, stoga pri svakoj novoj primjeni apsorpcija će na početku biti niža.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1.
Farmakokinetički i farmakodinamički nalazi pokazuju da se učinak supkutane injekcije inzulina glargina uglavnom temelji na izloženosti metabolitu M1.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with Lantus is principally based on exposure to M1.
Farmakokinetički i farmakodinamički nalazi pokazuju da se učinak supkutane injekcije lijeka Lantus uglavnom temelji na izloženosti metabolitu M1.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with Toujeo is principally based on exposure to M1.
Farmakokinetički i farmakodinamički nalazi pokazuju da se učinak supkutane injekcije lijeka Toujeo uglavnom temelji na izloženosti metabolitu M1.
The pharmacokinetic and pharmacodynamic properties of NovoRapid were investigated in children (6–12 years) and adolescents (13–17 years) with type 1 diabetes.
Farmakokinetička i farmakodinamička svojstva lijeka NovoRapid ispitivana su u djece (6-12 godina) i adolescenata (13-17 godina) sa šećernom bolešću tipa 1.
The pharmacokinetic data from HIV-infected pregnant women receiving REYATAZ capsules with ritonavir are presented in Table 9.
Farmakokinetički podaci prikupljeni u trudnica zaraženih HIV-om koje su uzimale REYATAZ kapsule s ritonavirom prikazani su u tablici 8.
The pharmacokinetic data in patients with von Willebrand disease are very similar to those observed in the adult population.
Farmakokinetički podaci za bolesnike s von Willebrandovom bolesti su vrlo slični podacima za odraslu populaciju.
The pharmacokinetic enhancing effect of cobicistat on darunavir was evaluated in a phase 1 clinical study GS-US-216-0115 in 31 healthy subjects that were administered darunavir 800 mg in combination with cobicistat 150 mg or ritonavir 100 mg, all once daily, for 10 days.
Farmakokinetički pojačavajući učinak kobicistata na darunavir procijenjen je u fazi 1 kliničkog ispitivanja GS-US-216-0115 u 31 zdravog ispitanika kojima je primijenjen darunavir 800 mg u kombinaciji s kobicistatom 150 mg ili ritonavirom 100 mg, sve jednom dnevno tijekom 10 dana.
The pharmacokinetic evaluation was performed at steady-state, after 1 or 3 months of treatment.
Farmakokinetička procjena je provedena u mirnom stanju, nakon 1 ili 3 mjeseca liječenja.
The pharmacokinetic interactions between rufinamide and other antiepileptic medicinal products have been evaluated in patients with epilepsy using population pharmacokinetic modelling.
Farmakokinetičke interakcije između rufinamida i drugih antiepileptičkih lijekova u bolesnika s epilepsijom procijenjene su pomoću populacijskog farmakokinetičkog modeliranja.
The pharmacokinetic parameters for Privigen were determined in a clinical study in PID patients (see section 5.1).
Farmakokinetički parametri za Privigen utvrđeni su u kliničkom ispitivanju u PID bolesnika (vidjeti dio 5.1).
The pharmacokinetic parameters from the chromogenic assay data were similar to those derived for the one- stage assay.
Farmakokinetički parametri iz podataka dobivenih kromogenim testom bili su slični onima dobivenima jednostupanjskim testom.
The pharmacokinetic parameters of Caelyx (primarily representing pegylated liposomal doxorubicin hydrochloride and low levels of unencapsulated doxorubicin hydrochloride) observed after the 20 mg/m2 doses are presented in Table 10.
Farmakokinetički parametri Caelyxa (koji primarno predstavljaju pegilirani liposomalni doksorubicinklorid i niske razine neinkapsuliranog doksorubicinklorida) izmjeren nakon doze od 20 mg/m2 prikazani su u tablici 10.
The pharmacokinetic parameters of elosulfase alfa were evaluated in 23 patients with MPS IVA who received weekly intravenous infusions of 2 mg/kg of elosulfase alfa over approximately 4 hours for 22 weeks and the parameters at Week 0 and Week 22 were compared.
Farmakokinetički parametri elosulfaze alfa procijenjeni su kod 23 ispitanika s MPS IV A koji su primili tjednu intravensku infuziju od 2 mg/kg elosulfaze alfa u trajanju od otprilike 4 sata tijekom 22 tjedna, a usporedili su se parametri u 0. tjednu i 22. tjednu.
The pharmacokinetic parameters of eltrombopag in paediatric subjects with ITP are shown in Table 10.
Farmakokinetički parametri eltrombopaga u pedijatrijskih ispitanika s ITP-om prikazani su u tablici 10.
The pharmacokinetic parameters of regadenoson have not yet been studied in the paediatric population (< 18 years).
Farmakokinetički parametri regadenosona još nisu ispitani u pedijatrijskoj populaciji (< 18 godina).
The pharmacokinetic parameters of tocilizumab did not change with time.
Farmakokinetički parametri tocilizumaba nisu se mijenjali s vremenom.
The pharmacokinetic parameters of total irinotecan and SN-38 analytes, following the administration of ONIVYDE 80 mg/m2 are presented in Table 5.
Farmakokinetički parametri analita ukupnog irinotekana i SN-38 nakon primjene lijeka ONIVYDE 80 mg/m2 prikazani su u Tablici 5.
The pharmacokinetic parameters quoted below are based on population parameter estimates for the 563 patients who received Benlysta 10 mg/kg in the two Phase III studies.
Niže navedeni farmakokinetički pokazatelji temelje se na procjenama populacijskih pokazatelja za 563 bolesnika koju su primali 10 mg/kg lijeka Benlysta u dvije studije Faze III.
The pharmacokinetic profile of a 20 mg dose of tasimelteon was compared among 8 subjects with mild hepatic impairment (Child-Pugh Score ≥5 and ≤6 points), 8 subjects with moderate hepatic impairment (Child-Pugh Score ≥7 and ≤9 points), and 13 healthy matched controls.
Farmakokinetički profil doze tazimelteona od 20 mg tazimeluspoređen je među 8 ispitanika s blagim oštećenjem funkcije jetre (Child-Pugh rezultat ≥ 5 i ≤ 6 bodova), 8 ispitanika s umjerenim oštećenjem funkcije jetre (Child-Pugh rezultat ≥ 7 i ≤ 9 bodova) te 13 zdravih odgovarajućih kontrola.
The pharmacokinetic profile of a 20 mg dose of tasimelteon was compared among 8 subjects with severe renal impairment (estimated glomerular filtration rate [eGFR] ≤ 29 mL/min/1.73m2), 8 subjects with end- stage renal disease (ESRD) (GFR < 15 mL/min/1.73m2) requiring hemodialysis, and 16 healthy matched controls.
Farmakokinetički profil doze tazimelteona od 20 mg uspoređen je među 8 ispitanika s teškim oštećenjem funkcije bubrega (procijenjena stopa glomerularne filtracije [eGFR] ≤ 29 mL/min/1,73 m2), 8 ispitanika sa završnim stadijem bolesti bubrega (GFR < 15 mL/min/1,73 m2) kojima je potrebna hemodijaliza, te 16 zdravih odgovarajućih kontrola.
The pharmacokinetic profile of Actrapid has been studied in a small number (n=18) of diabetic children (aged 6–12 years) and adolescents (aged 13–17 years).
Farmakokinetički profil lijeka Actrapid ispitan je u malog broja (n=18) djece (u dobi od 6–12 godina) i adolescenata (u dobi od 13–17 godina) sa šećernom bolešću.
The pharmacokinetic profile of cinacalcet in patients with mild, moderate, and severe renal insufficiency, and those on haemodialysis or peritoneal dialysis is comparable to that in healthy volunteers.
Farmakokinetički profil sinakalceta u bolesnika s blagom, umjerenom i teškom renalnom insuficijencijom, kao i u bolesnika na hemodijalizi ili peritonejskoj dijalizi, jednak je onoj u zdravih dobrovoljaca.
The pharmacokinetic profile of lutropin alfa is similar to that of urinary- derived hLH.
Farmakokinetički profil lutropina alfa sličan je hLH dobivenom iz mokraće.
The pharmacokinetic profile of teduglutide in this paediatric population, as evaluated by clearance and volume of distribution, was different from that observed in adults after correcting for body weights.
Farmakokinetički profil teduglutida u toj pedijatrijskoj populaciji, procijenjeno prema klirensu i volumenu distribucije, razlikovao se od onog opaženog u odraslih nakon korekcije za tjelesnu težinu.
The pharmacokinetic profile of Xultophy is consistent with once daily dosing and steady state concentration of insulin degludec and liraglutide is reached after 2–3 days of daily administration.
Farmakokinetički profil lijeka Xultophy u skladu je s doziranjem jednom dnevno, a koncentracija degludek inzulina i liraglutida u stanju dinamičke ravnoteže dostiže se nakon 2-3 dana svakodnevne primjene.
The pharmacokinetic properties described below have to a large extent been derived from a population pharmacokinetic analysis with data from 1507 patients with various types of advanced malignancies.
Farmakokinetička svojstva opisana u nastavku u velikoj su mjeri izvedena iz populacijske farmakokinetičke analize podataka prikupljenih u 1507 bolesnika s različitim vrstama uznapredovalih zloćudnih tumora.
The pharmacokinetic properties have not been investigated in patients with impaired liver function.
Farmakokinetička svojstva nisu ispitana u bolesnika s oštećenom jetrenom funkcijom.
The pharmacokinetic properties of 64Cu-labelled medicinal products prepared by radiolabelling with Cuprymina, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakokinetička svojstva 64Cu-obilježenih lijekova pripremljenih radioobilježavanjem s Cuprymina- om prije primjene, ovisit će o prirodi lijeka koji će biti radioobilježen.
The pharmacokinetic properties of aclidinium bromide in patients with moderate to severe COPD appear to be similar in patients aged 40–59 years and in patients aged ≥70 years.
Čini se da su farmakokinetička svojstva aklidinijeva bromida u bolesnika s umjerenim do teškim KOPB-om slična u bolesnika u dobi 40-59 godina i u bolesnika u dobi ≥70 godina.
The pharmacokinetic properties of enfuvirtide have been evaluated in HIV-1-infected adult and paediatric patients.
Farmakokinetička svojstva enfuvirtida ispitana su u odraslih i pedijatrijskih bolesnika zaraženih HIV-om.
The pharmacokinetic properties of Feraccru were also investigated at steady state in 15 subjects who were already participating in the AEGIS1/2 study described above and who had been in the open-label treatment phase for at least 7 days (Feraccru 30 mg twice daily).
Farmakokinetička svojstva Feraccrua također su ispitana u stanju dinamičke ravnoteže na 15 ispitanika koji su već sudjelovali u prethodno opisanoj studiji AEGIS1/2 te u liječenju u fazi otvorenog ispitivanja najmanje 7 dana (Feraccru 30 mg dvaput dnevno).
The pharmacokinetic properties of insulin degludec in children (1-11 years) and adolescents (12- 18 years) were at steady state comparable to those observed in adults with type 1 diabetes mellitus.
Farmakokinetička svojstva degludek inzulina u djece (1-11 godina) i adolescenata (12-18 godina) su u stanju dinamičke ravnoteže bila usporediva s onima zapaženima u odraslih sa šećernom bolešću tipa 1.
The pharmacokinetic properties of Levemir were investigated in young children (1–5 years), children (6–12 years) and adolescents (13–17 years) and compared to adults with type 1 diabetes.
Farmakokinetička svojstva lijeka Levemir ispitivana su u male djece (1-5 godina), djece (6-12 godina) i adolescenata (13-17 godina) i uspoređena s odraslima sa šećernom bolešću tipa 1.
The pharmacokinetic properties of Levemir were investigated in young children (1–5 years), children(6–12 years) and adolescents (13–17 years) and compared to adults with type 1 diabetes.
Farmakokinetička svojstva lijeka Levemir ispitivana su u male djece (1-5 godina), djece (6-12 godina) i adolescenata (13-17 godina) i uspoređena s odraslima sa šećernom bolešću tipa 1.
The pharmacokinetic properties of Luminity were evaluated in normal healthy subjects and subjects with chronic obstructive pulmonary disease (COPD) following intravenous administration of a
Farmakokinetička svojstva Luminityja bila su ocijenjena u normalnih zdravih ispitanika i u ispitanika s kroničnom opstruktivnom plućnom bolešću (KOPB) nakon intravenske primjene doze lijeka od
The pharmacokinetic properties of nintedanib were similar in healthy volunteers, cancer patients, and patients of the target population.
Farmakokinetička svojstva nintedaniba bila su slična u zdravih dobrovoljaca, bolesnika s rakom i bolesnika ciljne populacije.
The pharmacokinetic properties of Ryzodeg in type 1 diabetes mellitus were investigated in children (6–11 years) and adolescents (12–18 years) and compared to adults after single dose administration.
Farmakokinetička svojstva lijeka Ryzodeg kod šećerne bolesti tipa 1 ispitivana su u djece (6-11 godina) i adolescenata (12-18 godina) i uspoređena s odraslima nakon primjene jedne doze.
The pharmacokinetic properties of secukinumab observed in ankylosing spondylitis patients were similar to those displayed in plaque psoriasis patients.
Farmakokinetička svojstva sekukinumaba opažena u bolesnika s ankilozantnim spondilitisom bila su slična onima u bolesnika s plak psorijazom.
The pharmacokinetic properties of secukinumab observed in psoriatic arthritis patients were similar to those displayed in plaque psoriasis patients.
Farmakokinetička svojstva sekukinumaba opažena u bolesnika s psorijatičnim artritisom bila su slična onima u bolesnika s plak psorijazom.
The pharmacokinetic properties of the combination of Viekirax with dasabuvir have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Table 19 shows mean Cmax and AUC of Viekirax 25 mg/150 mg/100 mg once daily with dasabuvir 250 mg twice daily following multiple doses with food in healthy volunteers.
Farmakokinetička svojstva kombinacije lijeka Viekirax i dasabuvira ocijenjena su u zdravih odraslih ispitanika te u ispitanika s kroničnim hepatitisom C. U Tablici 19 navode se srednje vrijednosti Cmax i AUC-a lijeka Viekirax u dozi od 25 mg/150 mg/100 mg jedanput na dan u kombinaciji s dasabuvirom u dozi od 250 mg dvaput na dan nakon višekratnih doza primijenjenih s hranom u zdravih dobrovoljaca.
The pharmacokinetic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakokinetička svojstva lijekova označenih itrijem (90Y) pripremljenih radioaktivnim označavanjem lijekom Yttriga prije davanja pacijentu ovise o prirodi lijeka koji se radioaktivno označava.
The pharmacokinetic properties, use in special populations and drug-drug interactions for each of the individual components (lamivudine and raltegravir) are applicable to DUTREBIS.
Farmakokinetička svojstva, primjena u posebnim populacijama te interakcije između lijekova za svaku pojedinačnu komponentu (lamivudin i raltegravir) odnose se i na DUTREBIS.
The pharmacokinetic results for the co primary endpoint, Ctrough at pre dose Cycle 8 (Ctrough), showed non-inferiority of the Herceptin subcutaneous compared to the Herceptin intravenous dose adjusted by body weight.
Farmakokinetički rezultati za jednu od dvije primarne mjere ishoda, Ctrough prije primjene doze u 8. ciklusu (Ctrough), pokazali su neinferiornost supkutane doze lijeka Herceptin u usporedbi s intravenskom dozom lijeka Herceptin prilagođenom prema tjelesnoj težini.
The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).
Farmakokinetički podaci ukazuju da je poluvijek (5,3 h) kraći nego u odraslih (7,2 h), a prividni klirens (1,5 ml/min/kg) brži je nego u odraslih (0,96 ml/min/kg).
The pharmacokinetic results show that the clearance and volume of distribution of bevacizumab were comparable between paediatric and adult patients when normalized by body weight.
Farmakokinetički podaci pokazuju da su klirens i volumen distribucije bevacizumaba u pedijatrijskih i odraslih bolesnika usporedivi kada se normaliziraju za tjelesnu težinu.
The pharmacokinetic variability observed in the elderly is within the range for the non- elderly.
Farmakokinetička varijabilnost uočena u starijih osoba je unutar raspona za mlađe osobe.